Myelodysplastic Syndromes (MDS)

Swapna Thota, MD

Institution
University of Tennessee
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
As a physician caring for patients with acute leukemias and related disorders, I have a sustained focus on translational research in hematologic malignancies. Genomic sequencing technology revolutionized our understanding of cancer biology. My research focuses on exploring the dynamic changes of tumor immune microenvironment with clonal evolution of myeloid malignancies. Targeting inflammaging of bone marrow to impede clonal evolution is my ultimate professional goal and there by improve the survival rate for leukemia patients. My long-term goal is to develop potentially less toxic targeted

This is Your Brain on (Chemo) Drugs - Summer 2021 Conference

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Bone Marrow Transplant
Living Well with Bone Marrow Failure
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric Bone Marrow Failure Diseases
Related Bone Marrow Failure Diseases and Malignancies
Presenter(s)
Jorg Dietrich, MD, PhD
Dr. Jorg Dietrich will help patients and their loved ones understand the chemistry and biology behind what happens to patient brains when chemotherapy and other treatments are introduced. This is a great session for caregivers, family members and patients.

Dr. Elizabeth Bowhay-Carnes

Institution
UT Health - San Antonio
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Elizabeth Bowhay-Carnes is a Texas native and passionate about serving the people of her home community. She earned her bachelors of science degree in biochemistry from the University of Texas at Austin, followed by work with the MD Anderson Cancer Center Umbilical Cord Blood Bank in Houston. She received her medical doctorate from UT Health San Antonio and completed her residency in internal medicine and fellowship in hematology and medical oncology at the UT Health Science Center. She joined UT Health San Antonio MD Anderson Cancer Center in 2016 as Director of the Adult Non-Malignant

Dr. Amy Duffield

Institution
Mount Sinai Medical Center
Physician Status
available for consultation
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Dr. Duffield is a board-certified hematopathologist, specializing in the diagnosis of cancers that arise in the bone marrow and lymphoid tissues. She completed a pathology residency and hematopathology fellowship at the Johns Hopkins Hospital and joined the faculty of Johns Hopkins in 2010. In 2020, she joined Memorial-Sloan Kettering to become a member of the Hematopathology Service.

Constandina Herbert, MN, RN, BMTCN

Institution
Fred Hutchinson Cancer Research Center
Physician Status
available for consultation
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Constandina Herbert, MN, RN, BMTCN is the Nursing Supervisor, Blood and Marrow Transplant Clinic at the Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Ms. Herbert works with patients, families, and caregivers as they navigate the transplant process.

MDS and Agent Orange with Dr. David Steensma

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Related Bone Marrow Failure Diseases and Malignancies
Presenter(s)
David Steensma, MD, FACP
Dr. Steensma explains the relationship between Agent Orange and Myelodysplastic Syndromes in this webinar. Recorded on October 16, 2018

Anna Halpern, MD

Institution
Fred Hutchinson Cancer Research Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
I am both a hematologist-oncologist and a clinical researcher. Along with caring for you, I conduct research focused on hematologic (blood-based) malignancies — specifically, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), polycythemia vera, essential thrombocythemia and myelofibrosis. My overarching research aim is to help adults with these diseases have better outcomes by developing and testing evidence-based therapies that are tailored to your unique needs as a patient. I design and conduct clinical trials testing novel care concepts for people with AML and MDS, and I use

Kanwaldeep Mallhi, MD

Institution
Roswell Park Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Dr. Kanwaldeep Mallhi is a pediatric oncologist and hematologist who specializes in nonmalignant blood disorders in children. These disorders include immunodeficiencies, bone marrow failure and metabolic errors. She is an expert in pediatric blood stem cell transplants, and her research focuses on alternative donor sources and the development of reduced-intensity conditioning regimens, which use radiation, chemotherapy or other procedures to remove diseased or failing cells prior to transplant.

Azacitidine Improves RBC-TI Rates in Patients with Lower-Risk MDS

Original Publication Date
Article Source
External Web Content
CC-486—the oral formulation of azacitidine—significantly improved RBC transfusion independence (RBC-TI) rates and induced durable bilineage improvements in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high-risk disease features, according to a phase 3 clinical…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.